REC-2282 is under clinical development by Recursion Pharmaceuticals and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect REC-2282’s likelihood of approval (LoA) and phase transition for Neurofibromatoses Type II took place on 21 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their REC-2282 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

REC-2282 overview

REC-2282 is under development for the treatment of relapsed or refractory hematological malignancies including prostate cancer, vestibular schwannoma, meningioma, neurofibromatosis type 2. It was under development for the treatment of relapsed multiple myeloma, chronic lymphocytic leukemia (CLL), hodgkin lymphoma, non-hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, bladder cancer. The drug candidate is administered orally. AR-42 targets histone deacetylases (HDAC).

Recursion Pharmaceuticals overview

Recursion Pharmaceuticals (Recursion) is an artificial intelligence (AI)-driven biopharmaceutical company. It harnesses the potential of applying machine learning (ML) to complex biology to advance novel treatment options for diseases with high unmet medical needs. The company houses over four petabytes of biological images on its robotics platform which applies advanced ML to identify drug candidates and provide insights on potential toxicity, and mechanisms of action. It is advancing a pipeline of cardiovascular, metabolic, oncology, immunology, neuroscience, and infectious diseases models. The company also offers target discovery and lead optimization services to its partner companies for furthering their clinical investigation. Recursion is headquartered in Salt Lake City, Utah, the US.

Quick View REC-2282 LOA Data

Report Segments
  • Innovator
Drug Name
  • REC-2282
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.